微质向治疗可缓解由Cntnap4缺乏引起的认知障碍
Wenlong Zhang1,2,3,4, Huaqing Chen5, Liuyan Ding1,2
1Department of Neurology The First Affiliated Hospital of Guangzhou Medical University Guangzhou China.
Exploration (Beijing, China)
|November 7, 2023
概括
接触因相关蛋白类4 (Cntnap4) 的损失会损害记忆,并导致炎症. 一种针对微质细胞的新型纳米粒子药物递送系统有效地扭转了小鼠的这些认知缺陷.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 接触因相关蛋白类4 (Cntnap4) 对于大脑GABAergic传播至关重要.
- Cntnap4功能障碍与自闭症等神经系统疾病有关,但其在记忆中的作用尚不清楚.
研究的目的:
- 研究Cntnap4在认知功能和突触可塑性中的作用.
- 探索针对Cntnap4缺乏的微质介导炎症的治疗潜力.
主要方法:
- 产生雌性异质合体Cntnap4淘汰赛小鼠来研究认知缺陷.
- 开发了仿生微质纳米颗粒 (MNPs@PLX) 用于向输送PLX3397以抑制炎症.
- 评估认知功能,突触可塑性和促炎性标志物.
主要成果:
- 海马体Cntnap4缺乏导致雌性小鼠的认知功能受损和突触可塑性.
- MNPs@PLX成功穿越了血脑屏障,并准了微质细胞.
- MNPs@PLX治疗减轻了认知衰退,突触功能障碍和神经炎症.
结论:
- 失去Cntnap4会通过功能障碍的GABAergic传播诱导促炎性认知衰退.
- 使用MNP@PLX针对微质功能,为Cntnap4相关的神经认知障碍提供了一个有前途的治疗策略.
更多相关视频
相关概念视频
01:22Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
130
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
130